PCSK9 inhibitors: current status and emerging frontiers in lipid control-Reference-Cited by-同舟云学术

PCSK9 inhibitors: current status and emerging frontiers in lipid control

Published:2023-11-23 Issue: Volume: Page:1-18
ISSN:1477-9072
Container-title:Expert Review of Cardiovascular Therapy
language:en
Short-container-title:Expert Review of Cardiovascular Therapy

Author:

Agnello Federica¹,Mauro Maria Sara¹,Rochira Carla¹,Landolina Davide¹,Finocchiaro Simone¹,Greco Antonio¹,Ammirabile Nicola¹,Raffo Carmelo¹,Mazzone Placido Maria¹,Spagnolo Marco¹,Occhipinti Giovanni¹,Imbesi Antonino¹,Giacoppo Daniele¹,Capodanno Davide¹

Affiliation:

1. Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico “G. Rodolico – San Marco”, University of Catania, Catania, Italy

Publisher

Informa UK Limited

Subject

Cardiology and Cardiovascular Medicine,General Medicine,Internal Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14779072.2023.2288169

Reference97 articles.

1. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019

2. A review of polypills for the prevention of atherosclerotic cardiovascular disease

3. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel